Venetoclax/Venetoclax (Vekela) dosage reference and individualized adjustment plan

Venetoclax is an oral BCL-2 inhibitor, mainly used to treat hematological tumors such as chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML). Its mechanism of action is to induce tumor cell apoptosis by inhibiting the anti-apoptotic protein BCL-2. Standard dosages vary depending on the indication and combination regimen. Taking CLL as an example, the starting dose for adults usually starts from 20mg once a day and increases to 5 weeks. >400mgTarget dose once daily; AMLWhen combined with low-dose azacitidine or decitabine, the recommended dose is 400mgonce daily, which can be adjusted based on tolerance.

The dose adjustment of venetoclax should be based on the patient's tumor burden, renal function, liver function and hemogram. In patients with renal insufficiency or impaired hepatic function, a lower initial dose or a longer escalation cycle may be necessary to reduce the risk of tumor lysis syndrome (TLS). Patients with light body weight, severe infection, or bone marrow suppression can also choose a slower dose escalation plan under the guidance of a doctor. The core of individualized adjustment is to balance efficacy and safety to ensure that the drug can fully inhibit tumors without causing serious side effects.

In the initial incremental phase, a daily or weekly incremental regimen is usually adopted. At the same time, blood biochemistry monitoring is required during the first dose and dose adjustment period, focusing on indicators such as serum potassium, serum phosphorus, creatinine, and uric acid to prevent the occurrence of TLS. High-risk patients can be monitored in hospital under hospital conditions with adequate hydration and pharmacological prophylaxis. Once the target dose is reached and well tolerated, treatment can be continued at this dose, and blood and tumor indicators can be followed regularly to evaluate efficacy and safety.

Successful use of venetoclax relies on strict adherence to dose escalation and individualized adjustments. Patients should be followed up regularly and report adverse reactions in a timely manner, such as fever, infection, thrombocytopenia or symptoms related to tumor lysis syndrome. Doctors can fine-tune the dose based on blood images, kidney and liver function and efficacy indicators, and if necessary, combine it with other targeted drugs or chemotherapy regimens to optimize the treatment effect. Through scientific dosage management and individualized adjustment, patients can not only obtain maximum anti-tumor efficacy, but also reduce the risk of serious side effects and achieve safe and standardized long-term treatment.

Reference materials:https://www.drugs.com/